When evaluating tumor volumes as defined by anatomical MRI, no significant differences were observed between responders and non-responders at baseline, and three and seven days following M002 and anti-PD1 (p > 0.05), resembling anatomical MRI limitations observed in clinical immunotherapy studies. Here, PDCD1 is linked to neoplasm.